人类动脉粥样硬化的生命历程连续体：发病、患病率、载脂蛋白B的因果关系与饮食调整

摘要

人类 动脉粥样硬化 通常作为一种衰老相关疾病来管理，然而病理记录将其最早的 病变 在出生前及其在大部分中年成年人中通过影像学可检测到的表现。本文综合了胎儿、儿童、尸检和人群影像学文献，以确定该疾病何时开始、其患病率如何，以及是什么将真正的病理学与正常动脉发育区分开来。我们认为 适应性内膜增厚 必须与脂质潴留性病变进行本质上的区分，并且未能作出这种区分解释了历史尸检文献中的大部分分歧，包括年轻军人死者中冠状动脉粥样硬化表面上持续六十年的下降。我们随后检查了识别 载脂蛋白 含硼的 脂蛋白 作为必要的起始底物以及累积暴露模型的统一 孟德尔随机化, ，儿科 家族性高胆固醇血症 队列研究以及随机降脂试验。来自以谋生为基础的生活群体和前工业化时期木乃伊遗骸的比较证据被用来检验动脉粥样硬化是衰老的必然结果这一说法。我们回顾了降低终生患病风险的饮食策略 载脂蛋白B 儿童和成人的暴露情况，探讨多不饱和植物油这一备受争议的问题，并明确指出高患病率的亚临床病变意味着什么以及不意味着什么。附录记录了来源验证结果，包括对二手文献中经常误报的声称的修正数据。.

索引词

载脂蛋白B，动脉粥样硬化，, 累积暴露, ，膳食脂肪，家族性的 高胆固醇血症, ，胎儿起源，, 内膜增厚, ，低密度脂蛋白，预防心脏病学。.

I. 引言

动脉粥样硬化通常被当作一种晚年疾病来管理。病理记录并不支持这种界定。最早期的病变在出生前就已经出现，到了三十岁时，相当一部分人群就已经带有能够进展的病变[5], [6该疾病是一个终生的连续过程，而非晚期事件。.

这产生了一个概念上的问题：如果动脉病变到了晚年变得非常普遍，那么在什么意义上动脉粥样硬化还是一种疾病呢？要回答这个问题，需要两个条件：一是区分适应与病理的组织学界限，二是解释为什么这一病理过程在某些人群中进展迅速而在另一些人群中进展缓慢的因果模型。.

第二部分和第三部分确立了组织学框架和尸检证据，包括扭曲了对历史军事病例系列之解读的方法学异质性。第四部分构建了载脂蛋白B（apoB）累积暴露模型。第五部分评估了进化假说。第六部分和第七部分探讨了饮食调整。第八部分阐明了亚临床病变的普遍存在所代表和不代表的意义。各项数字主张均已与原始资料进行了核对；不一致之处记录在附录中。.

II. 区分动脉适应与疾病

A. 组织学边界

动脉壁由三层构成： 内膜, ，由单层 内皮细胞; 肌肉层；以及外层 外膜. 在出生后早期以及几乎所有成年人中，内膜在血流受到干扰的分支点和弯曲处局灶性增厚。适应性内膜增厚的特征主要表现为 平滑肌细胞 在蛋白聚糖-胶原基质内，并且与保留脂质的动脉粥样硬化病变不同，缺乏脂质积聚和炎性泡沫细胞浸润的典型特征1], [2].

Stary 为美国心脏协会制定的分类1] 并由 Virmani 及其同事 [2] 按进展排列后续病变。 内膜黄色瘤, 历史上被称为 脂纹, ，是涉及脂质的首个病变： 含载脂蛋白B的颗粒 穿过 内皮, ，保留在内皮下基质中，并被吞噬 巨噬细胞 变得充满脂质 泡沫细胞. 随后是病理性内膜增生，其特征为深部内膜出现无细胞的细胞外脂质池以及局部的平滑肌细胞丢失。 纤维粥样斑块 是第一个真正的病变吗 坏死核心 在...下方 纤维帽. 。 薄帽纤维粥样硬化斑块, ，其中炎症性蛋白水解将纤维帽厚度减少至65微米以下，是与斑块破裂和急性发作最相关的表型 冠状动脉血栓形成 [2]. 图 1 根据证据基础总结了这一进展。.

就本综述而言，其操作性标准是：当血管发现涉及含apoB脂蛋白的潴留和修饰，并伴有细胞损伤或炎症浸润时，即构成病变，无论该病变是微观的、无症状的还是可逆的。适应性内膜增厚不符合这一标准；内膜 黄瘤 这样做。.

B. 为什么该区别决定了法律解释

这条分界线不仅仅是分类学上的。病理学家如果将任何内膜增厚都判定为动脉粥样硬化，其报告的患病率将大大高于只将那些保留脂质、呈炎症性病变的病变判定为动脉粥样硬化的病理学家。由于历史上的尸检文献跨越了数十个诊断标准和制备方法不断演变的时期，如果不把定义、制备方法和分级标准上的差异考虑在内，不同时代的患病率数据就无法直接进行对比。第三节将探讨其后果。.

III. 全生命周期的尸检证据

A. 胎儿和儿童早期病变

Napoli 及其同事对 82 例胎儿进行了研究 主动脉 来自自然流产和出生后十二小时内死亡的早产儿，平均胎龄为 6.2 ± 1.3 个月 [3]。标本根据母亲进行分组 胆固醇 状态：22名来自胆固醇水平正常的母亲，33名来自高胆固醇血症母亲，27名仅在妊娠期间患有高胆固醇血症的母亲。含有天然和氧化低密度脂蛋白的脂肪条纹（低密度脂蛋白）存在于胎儿主动脉中，且高胆固醇血症母亲的胎儿病变范围更大。在小于六个月的胎儿中，胎儿血浆胆固醇与母体胆固醇相关（R = 0.86，P = 0.001），且胎儿胆固醇随胎龄下降（R = −0.88）。低密度脂蛋白（LDL）的积聚和氧化修饰先于单核细胞的招募，这与“反应性潴留”（response-to-retention）而非“反应性损伤”（response-to-injury）的起始顺序一致。3].

根据第二条A款的标准，这些是真正的病变。然而，它们并不表明胎儿脂质积聚必然会进展为临床疾病。儿童早期病变转归（FELIC）研究检查了156名1至13岁血脂正常的儿童的主动脉，发现年龄最小的儿童的主动脉病变比相应的胎儿要小，这与宫内暴露结束后产后消退的情况相符[4随后，两组暴露人群的病变大小均随着年龄增长而增加，且高胆固醇血症母亲的孩子病情进展更快，尽管这些孩子自身的胆固醇水平正常。因此，早期病变的轨迹受后续暴露的强烈影响，并非在形成时就一成不变。.

B. 青春期与青年期

青少年动脉粥样硬化的病理生物学决定因素（PDAY) 该项目检查了因外部原因死亡的 15 至 34 岁人群的动脉。报告的样本量在不同的 PDAY 出版物中有所不同，并且是反复引起混淆的根源：1993 年的自然史分析报告了 1,532 名受试者 [5]，2000年地形分析 2,876 [6]。两者对于各自的分析都是正确的。.

在最年轻的 PDAY 层（15至19岁年龄组），所有胸主动脉和腹主动脉以及约一半的右侧 冠状动脉 带有肉眼可见的嗜苏丹性病变5]。病变范围随年龄呈单调增加，且病变负担与以下死后标志物相关： 非高密度脂蛋白胆固醇, 吸烟 由血清硫氰酸盐、肥胖和血糖指数表示6]。与白人受试者相比，黑人受试者表现出更广泛的脂肪条纹，而进展为隆起性病变则遵循常规 风险因素.

由这些死后关联得出的PDAY风险评分随后预测了活体队列中的临床结果。在 冠状动脉风险发展至成年研究 研究显示，得分每增加一个标准差，心血管事件的发生率就会预测有 风险比 在十五年内从 1.74 到 2.04，C 统计量为 0.77 至 0.79 [7]。该评分还预测了颈动脉 内膜中膜厚度 在“年轻芬兰人心血管风险”队列中39]。这支持了青少年尸检中观察到的病变与几十年后临床显现的疾病之间的生物学连续性。.

这 博加卢萨心脏研究 将204名年龄在2至39岁且其中93人拥有先前危险因素数据的个体的、前瞻性测量的生前危险因素与尸检病理学联系起来8]. 病变负荷随危险因素数量的增加而逐步上升。当存在 0、1、2 和 3 至 4 个危险因素时，主动脉内膜表面被脂肪条纹覆盖的面积分别为 19.1%、30.3%、37.9% 和 35.0%；冠状动脉脂肪条纹值分别为 1.3%、2.5%、7.9% 和 11.0%；冠状动脉纤维性 斑块 参与度从0.6%上升到7.2%。对该研究的简写引文经常只报告冠状动脉系列的两个端点，从而掩盖了中间层。.

C. 军事系列与可比性问题

埃诺及其同事报告称，在阵亡于朝鲜的300名美国士兵中，有77.3%存在肉眼可见的冠状动脉疾病证据，平均年龄为22.1岁 [9] 随后对105例越南战争时期伤亡人员的一系列研究报告显示，45%的人患有冠状动脉粥样硬化，其中5%为严重病变 [10]. Webber及其同事对在伊拉克和阿富汗阵亡的3,832名现役军人（平均年龄25.9岁）进行了研究，结果显示8.5%的人存在任何形式的冠状动脉粥样硬化，其中重度占2.3%，中度占4.7%，轻微占1.5% [11]. 2021年对特种作战人员的一项分析发现，17.4%的人患有冠状动脉或主动脉粥样硬化，5.1%的人患有严重的冠状动脉疾病 [12].

跨越六个年代从77.3%下降到8.5%，可能反映了暴露情况的真实变化、不同序列之间的方法学差异，或两者兼有11]。仅凭这些尸检系列无法在它们之间进行分配，因为它们的病例选择、标本制备和分级标准各不相同。Enos 系列对未固定、塌陷的动脉进行大体肉眼评估，其疾病阈值从纤维性内膜增厚延伸至闭塞性斑块；按照现代标准，该阈值可能捕捉到现在会被归类为适应性内膜增厚而非动脉粥样硬化的病变。PDAY 则使用 10% 中性缓冲福尔马林进行标准化固定，并进行中央实验室苏丹 IV 染色以及由三位病理学家进行独立分级[5]，现代军事系列则再次应用了不同的严重程度阈值。韦伯（Webber）及其同事将这种下降归因于真实或人工制造的现象 [11]。关于年轻成人中冠状动脉粥样硬化几乎已经消失的结论，并不支持原始比较所显示的那么大的幅度。.

D. 中年及晚年

在 PESA 队列 对于40至54岁的无症状成年人，, 亚临床动脉粥样硬化 在所有被调查的地区中占63%13]. 在 SCAPIS, ，该研究共纳入超过25,000名年龄在50至64岁之间、无已知冠心病的瑞典成年人，通过冠状动脉计算机断层扫描血管造影术（CCTA）发现42.1%的人患有动脉粥样硬化，其中显著的 狭窄 在 5.2% 中；5.5% 的冠心病患者 钙化积分 尽管得分为零，依然检测出了冠状动脉粥样硬化 [14]. 血管内超声 对健康心脏移植供体冠状动脉的研究表明，在20岁以下的供体中，17%存在动脉粥样硬化；在40多岁（第四个十年）的供体中，这一比例为60%；而在50岁及以上的供体中，这一比例达到85% [15表I总结了主要研究。.

必须保留两个区别。首先，任何动脉粥样硬化、阻塞性狭窄和临床显现的疾病都不是可互换的终点：SCAPIS 在一个42.1%的人群检测到斑块的研究中发现有5.2%的人群存在显着狭窄 [14其次，患病率取决于检查方法，特别是钙化积分对于早期和非钙化病变具有特异性但缺乏敏感性。14] 源验证期间确定的显著较高的阻塞性狭窄患病率估计值，无法与此处回顾的人口成像文献（附录，第 10 项）相调和。.

图 1. 人类生命周期中病变阶段的进展及支持证据。适应性内膜增厚（上方条带，左侧）是针对血流动力学应激的生理反应，并非疾病 [1], [2]。病理学始于内膜黄色瘤，其中含载脂蛋白B的脂蛋白被滞留并修饰2], [16]。早期脂质潴留病变已被证明具有可逆性[4]. 方括号中的数字指代参考文献列表。年龄轴经过压缩，且不是线性的。.

表 I

动脉粥样硬ification发生和患病率的主要尸检和影像学研究

学习	设计与国家	样本和年龄	方法	主要发现
那不勒斯等人 [3]	胎儿尸检系列；意大利	82条主动脉；平均胎龄6.2个月	组织学；载脂蛋白B、氧化低密度脂蛋白、CD68免疫染色	胎儿主动脉可见脂肪纹；母体高胆固醇血症时其范围更大；脂质潴留和氧化先于单核细胞募集
FELIC [4]	儿童尸检系列；意大利	156名年龄在1-13岁的儿童	计算机辅助形态测量学	最小儿童的病变比对应的胎儿小，表明出生后可消退；母体高胆固醇血症会加快病变进展
PDAY [5], [6]	多中心尸检计划；美国	1,532 (1993年)；2,876 (2000年)；15–34岁	标准化福尔马林固定；苏丹IV；中心分级	在15至19岁年龄段，所有主动脉和约半数右冠状动脉均已出现病变；病变严重程度与非高密度脂蛋白胆固醇、吸烟、肥胖以及血糖水平相关。
博加卢萨8]	与尸检关联的队列；美国	204例年龄在2–39岁之间的尸检；93例具有生前数据	大体染色；形态计量学	病变负担随儿童期危险因素数量的增加而逐步加重；冠状动脉纤维斑块从0.6%增加至7.2%
Enos 等人 [9]	战伤尸检；朝鲜	300名男性；平均年龄22.1岁	肉眼观察；未固定动脉	77.3%中的冠状动脉疾病；分级标准包括纤维性内膜增厚，因此其患病率可能高于当前病变定义所显示的水平
韦伯等人 [11]	伤亡尸检登记处；美国	3,832；平均年龄 25.9 岁	标准化尸检分级	任何冠状动脉粥样硬化 8.5%；重度 2.3%；历史数据中的下降趋势可能既反映了长期趋势，也反映了方法学上的差异
Tuzcu 等人 [15]	移植供体成像；美国	跨成年年龄段的供体心脏	血管内超声	Atherosclerosis in 17% of donors under 20 y, 60% in fourth decade, 85% at 50 y and older
PESA [13]	Asymptomatic cohort; Spain	Adults aged 40–54 y	Multiterritorial ultrasound and calcium scoring	Subclinical atherosclerosis in 63% in at least one territory
SCAPIS [14]	Population cohort; Sweden	>25,000 adults aged 50–64 y	冠状动脉CT血管成像	Coronary atherosclerosis 42.1%; significant stenosis 5.2%; 5.5% of those with calcium score zero had plaque

IV. Apolipoprotein B and Cumulative Exposure

A. The Initiating Substrate

Every atherogenic lipoprotein particle — LDL, its precursors 极低密度脂蛋白 以及 IDL, ，和 脂蛋白(a) — carries a single molecule of apolipoprotein B. Measurement of 低密度脂蛋白胆固醇 quantifies the cholesterol mass transported; measurement of apoB quantifies particle number. Because atherosclerosis is initiated by arterial retention of apoB-containing particles, particle number rather than cholesterol cargo is the mechanistically relevant exposure variable [16], [41].

We state the causal claim precisely. Arterial retention of apoB-containing lipoproteins is a necessary initiating event in the prevailing causal model of atherosclerosis [16], [41]; local vascular biology — endothelial permeability, proteoglycan composition, disturbed flow, and inflammatory signaling — determines where and when retention occurs. This formulation preserves the causal argument while acknowledging that lesion localization is not explained by particle concentration alone. It is consistent with the observation that lesions form preferentially at branch points and bends, where adaptive intimal thickening and disturbed flow coincide.

Three independent evidence streams converge on this conclusion: mechanistic studies of retention and oxidative modification within the arterial wall [41]; genetic studies showing that lifelong lower exposure to apoB-containing lipoproteins is associated with substantially lower coronary risk [42]; and randomized trials of pharmacological LDL reduction demonstrating event reduction proportional to absolute LDL lowering [43]. These streams are synthesized in [16] and [17].

B. The Cumulative-Exposure Model

Because retained particles accumulate over time, 斑块负荷 reflects the integral of apoB concentration over years of exposure, expressed as 胆固醇年 或 载脂蛋白B年 by explicit analogy with 包-年 of cigarette exposure [17]; the empirical support for that model is set out in [18] and [19] below. Pooled cohort analysis shows that cumulative LDL-C exposure during young adulthood and middle age predicts later cardiovascular events independently of midlife LDL-C level [18]. In CARDIA, among 4,366 participants followed from ages 18 to 40, each standard-deviation increase in cumulative apoB exposure was associated with a hazard ratio of 1.53 (95 percent 置信区间 1.36 to 1.72) for incident atherosclerotic 心血管疾病 after age 40, attenuating to approximately 1.30 after covariate adjustment [19].

The model supports an empirical inflection rather than a fixed threshold: in the same cohort, hazard increased above a usual apoB exposure of about 75 mg/dL per year across ages 18 to 40 [19]. This is a cohort-derived value, not a biological constant, and the authors present it as a potential clinical target requiring validation. The larger round numbers frequently quoted in secondary literature — 5,000 to 6,000 mg/dL-years of cumulative LDL, or 1,300 to 1,500 mg/dL-years of apoB — are modeling heuristics without direct empirical derivation. The associated milestones, namely that 纯合子型家族性高胆固醇血症 crosses such a threshold in childhood, heterozygous familial hypercholesterolemia in early adulthood, and average Western exposure near midlife, are illustrative consequences of the model and broadly consistent with observed 流行病学; the specific ages are not measured values.

C. Evidence From Early Intervention

The twenty-year follow-up of 他汀 therapy initiated in childhood for familial hypercholesterolemia provides one of the strongest available human demonstrations of the exposure model [20]. Treated patients exhibited carotid intima-media thickness progression comparable to unaffected siblings. At age 39, cumulative incidence of cardiovascular events was 1 percent among treated patients versus 26 percent among their affected parents, and cardiovascular mortality was 0 versus 7 percent.

This result is often summarized as a twenty-five-fold reduction in adult coronary events. That framing overstates the inferential strength of the design: the comparison is between treated offspring and their untreated parents, a non-randomized cross-generational contrast confounded by secular improvement in cardiovascular care. The findings strongly support benefit from early treatment, but the cross-generational comparison should not be interpreted as a causal fold-reduction estimate.

V. The Evolutionary Hypothesis

The material in this section is hypothesis rather than established explanation, and is presented at a lower evidentiary tier than Sections III and IV. It is included because it bears on the interpretive question of whether atherosclerosis is inevitable, but no part of the causal argument depends on it.

A. Antagonistic Pleiotropy

The apoB transport system serves essential functions in cholesterol transport and hepatic lipid export [41]. A role in innate host defense has also been described: apoB binds and sequesters a Staphylococcus aureus quorum-sensing peptide, limiting expression of the virulence genes required for invasive infection [44]. One proposed evolutionary interpretation of the late-life costs of such a system invokes 拮抗多效性, under which selection favors variants maximizing fitness during the reproductive period even when those variants impose costs over a post-reproductive interval where selection pressure is attenuated [45]. Such traits have been hypothesized to confer advantages under infectious and nutritional pressures, becoming maladaptive under sustained apoB elevation across an extended modern lifespan. This account is coherent and consistent with the comparative data below, but it has not been tested directly in humans and should not be treated as demonstrated.

B. Comparative Population Evidence

这 齐曼人, a forager-horticulturalist population of the Bolivian Amazon, provide striking evidence that low lifetime exposure is compatible with near-absence of coronary 钙化 in old age. Among 705 adults aged 40 years and older, 85 percent had a 冠状动脉钙化积分 of zero; among those older than 75 years, 65 percent had a score of zero and 8 percent had a score of 100 or greater [21]. This is a five-fold lower prevalence of significant coronary calcification than the 梅萨 reference population, observed despite substantial infectious and inflammatory burden [21].

O’Keefe and colleagues [22] have argued that physiologically normal LDL cholesterol for humans lies between 50 and 70 mg/dL, drawing comparisons with values reported in human neonates, wild non-human primates, and the least-exposed human populations. On this view, conventional laboratory reference intervals describe a population with pathological exposure rather than a healthy reference state. That argument is advanced in a 叙述性综述 and opinion article rather than original research, and several of its comparative lipid values are asserted with limited primary documentation. It is cited here as a synthesis of a position, not as primary evidence, and the underlying comparative values warrant independent verification.

Countervailing evidence comes from the 荷鲁斯研究, which performed whole-body 计算机断层扫描 on 137 mummified remains from four preindustrial cultures spanning more than four millennia [23]. Arterial calcification was identified in 47 of 137 remains, 34 percent, in all four populations including the Unangan hunter-gatherer group. Mean age at death was higher among affected than unaffected individuals, reproducing the age association seen in living populations.

These findings are reconcilable. Interpretation is limited by potential selection of preserved remains, uncertain representativeness of the sampled populations, and incomplete information regarding historical environmental exposures. Calcification detected by computed tomography is a late marker insensitive to early disease. The defensible synthesis is that atherosclerosis is an inherent potential of the human 动脉 whose rate and clinical expression are strongly modifiable, with lifetime exposure to apoB-containing lipoproteins a major modifiable determinant.

VI. Dietary Modification of Lifetime Exposure

A. Patterns With Established LDL Effect

The dietary portfolio approach, combining viscous soluble 纤维, plant 甾醇, soy 蛋白质, and tree nuts within a plant-based pattern, produces LDL reduction approaching that of a low-dose first-generation statin [24]. The Mediterranean pattern, tested in PREDIMED, a large dietary intervention trial whose 2018 report reanalyzed the data after documented departures from the 随机化 protocol at some sites, reduced cardiovascular events, with benefit observed despite high total fat intake from 橄榄油 and nuts rather than through fat restriction [25]. Vegetarian and vegan patterns lower LDL cholesterol relative to omnivorous comparators in randomized trials [46].

B. Pediatric Safety

Two randomized trials address the principal objection to lipid-lowering diets in children, namely impairment of growth or neurodevelopment. The Dietary Intervention Study in Children randomized 663 children aged 8 to 10 years with elevated LDL to a reduced-fat, reduced-cholesterol pattern for a mean of seven years, observing LDL reduction with no adverse effect on height, growth velocity, iron status, or sexual maturation [26]. The Special Turku Coronary Risk Factor Intervention Project initiated dietary counseling at seven months of age and reported cholesterol reduction without impairment of growth [27]; a separate analysis within the same cohort found no adverse effect on neurologic development at age five [40]. Pediatric guidelines nonetheless caution against fat restriction in infancy. The current U.S. integrated pediatric guideline recommends human milk or iron-fortified formula through the first year without fat modification, and for toddlers aged 12 to 24 months with a 家族史 的 肥胖, cardiovascular disease, or hypercholesterolemia, transition to reduced-fat milk only after discussion with the pediatric care provider and only within an overall diet supplying about 30 percent of calories from fat [47].

C. Very-Low-Fat and Added-Oil-Restricted Patterns

Patterns restricting total fat and eliminating added oils, including oils incorporated into prepared foods, rest on a different evidentiary basis. The 生活方式心脏试验 reported 血管造影消退 of coronary stenosis under a very-low-fat 以植物为主的饮食 [28], but delivered the diet within a bundle including exercise, stress management, and smoking cessation, so the independent contribution of oil restriction cannot be isolated; supporting clinical work in this tradition includes uncontrolled case-series evidence such as [29]. Their cardiovascular plausibility rests principally on favorable effects on established risk factors, including LDL-C and apoB. The position exceeds the evidence when it asserts that dietary oils are uniquely harmful beyond their energy density, or that very-low-fat patterns outperform higher-fat Mediterranean patterns for hard endpoints; the available randomized cardiovascular-outcome evidence does not establish that hierarchy.

VII.  Polyunsaturated Vegetable Oils

Substitution of polyunsaturated for 饱和脂肪 remains a prominent contemporary dietary debate about how to lower lifetime apoB exposure, and is addressed here for that reason. The supporting evidence is substantial. The Cochrane review of saturated fat reduction included 15 randomized trials and 56,675 participants; in the 12 trials contributing 53,758 participants to the combined cardiovascular events analysis, reducing saturated fat produced a 17 percent relative reduction (risk ratio 0.83; 95 percent confidence interval 0.70 to 0.98; 年级 moderate-quality evidence). The review concluded that replacing saturated fat with 多不饱和脂肪 或与 碳水化合物 each appeared useful, that subgrouping did not suggest significant differences between replacement with polyunsaturated fat and replacement with carbohydrate, and that data on replacement with monounsaturated fat and protein were very limited [30]. The American Heart Association Presidential Advisory estimated, in its synthesis of those trials, a reduction in cardiovascular disease of approximately 30 percent [31]. A pooled analysis of 30 前瞻性队列 found higher circulating 亚油酸 associated with lower incident disease and mortality [32], and controlled feeding trials have not demonstrated significant increases in C反应蛋白, interleukin-6, or tumor necrosis factor alpha with increased linoleic acid intake [33], [34].

Two lines of evidence raise concern. A single high-fat meal transiently impairs brachial artery flow-mediated dilation, resolving within about six hours [35]; the effect is not specific to 种子油, since the same investigators observed it following olive oil meals [36]. Separately, reanalyses of recovered data from two historical trials found higher mortality in the intervention arms: the Sydney Diet Heart Study reported 全因死亡率 of 17.6 versus 11.8 percent [37], and the Minnesota Coronary Experiment found greater cholesterol reduction associated with higher mortality [38]. Both recovered-data analyses carry important design and data limitations, including incomplete recovery of original records [37], [38]. Trans fat exposure from period-typical margarines is a plausible contributor but was not measured between groups and remains debated, including by the authors of the reanalyses; it should not be presented as an established explanation. The Sydney intervention used safflower oil, which contains no 欧米伽-3脂肪酸.

The two bodies of evidence are asymmetric. The apoB-lowering mechanism is supported by mechanistic, human genetic, and randomized outcome evidence [16], [41]-[43]; the 餐后 signal rests on a transient surrogate that has not been shown to predict hard outcomes when elicited by a meal. The trial reanalyses are genuinely discordant and should not be dismissed, but their methodological limitations render them insufficient, in isolation, to outweigh the aggregate randomized and prospective evidence. Taken together, the evidence supports dietary patterns that reduce lifetime apoB exposure and does not establish polyunsaturated vegetable oils as a primary vascular hazard [30]-[34], [37], [38].

VIII.  What “Everyone Has Atherosclerosis” Means

The claim that atherosclerosis is universal is frequently deployed to argue that it is therefore normal. The evidence assembled here supports a more specific statement.

Lipid-retaining arterial lesions become very common with advancing age. The stronger claim that nearly all adults eventually develop microscopic lipid-retaining pathology is not established by the imaging cohorts cited here and would require direct age-spanning histopathologic evidence. Such lesions should not be conflated with obstructive coronary disease, 斑块破裂, or clinical cardiovascular events, which remain minority outcomes relative to the prevalence of plaque. SCAPIS found detectable coronary atherosclerosis in 42.1 percent of adults aged 50 to 64 but significant stenosis in 5.2 percent [14]. Lifetime exposure to apoB-containing particles is a major determinant of lesion initiation and progression, although local vascular biology and other risk factors influence lesion fate.

Statistical ubiquity is therefore not evidence of physiological normality. 高血压 以及 胰岛素抵抗 are also common in aging Western populations without thereby constituting healthy reference states. The Tsimane findings argue against coronary calcification being an unavoidable consequence of human aging [21], although no single observational cohort is definitive. The FELIC observation of postnatal lesion regression indicates that early lesions are not committed to progression [4].

IX. Conclusion

The capacity for atherosclerosis is intrinsic to the human artery. Sustained exposure to apoB-containing lipoproteins promotes intimal lipid retention over time [16]; fetal aortic histology demonstrates that this can begin before birth [3], and the preindustrial mummy record shows that it is not uniquely modern [23]. In this limited sense the susceptibility is universal; the resulting lipid-retaining lesion is nonetheless pathological.

The rate of progression and its clinical expression are not fixed. The Tsimane population demonstrates that advanced age can occur with remarkably low coronary artery calcium burden [21], and individuals with familial hypercholesterolemia treated from childhood exhibit vascular trajectories approximating unaffected siblings [20]. Because cumulative exposure to apoB-containing particles is a major causal and modifiable determinant of disease burden [16]-[19], the high prevalence of atherosclerosis in later life is an argument for early and sustained exposure reduction rather than for therapeutic fatalism.

Appendix: Source Verification Record

The following documents discrepancies, unverifiable claims, and overstatements identified during verification. Items are retained because several affected claims circulate widely in secondary literature.

1) Napoli et al., fetal aortas. Sample composition, mean fetal age, and both correlation coefficients confirmed. Not confirmed: whether the primary report gives lesion prevalence percentages (commonly cited as 30 percent versus up to 90 percent by maternal status) or only lesion area; the abstract emphasizes area and extent. Correction to an earlier verification note: the lesion-composition values of 17.3 percent (native LDL only), 13.3 percent (氧化低密度脂蛋白 without macrophages), and 58.6 percent (both) are stated in the published abstract and are not suspect. They are percentages of immunopositive atherogenic sites, not of fetuses, which is the denominator most often lost in secondary citation. They are therefore omitted from prevalence statements in this paper.

2) FELIC lesion regression magnitude. Postnatal regression is reported in the primary study and is stated qualitatively here. The specific figure of 64 percent smaller lesions in children under three years, frequently quoted in secondary sources, was not verified against the primary text and is not asserted.

3) PDAY sample size. The discrepant values of 1,532 and 2,876 are both correct, corresponding to the 1993 natural-history and 2000 topographic analyses. The exact intimal-surface pairs sometimes quoted (2.2 to 12.2 percent in white men; 3.1 to 15.4 percent in black men) were not verified against source tables and are not reported numerically.

4) Bogalusa risk-factor gradient. All four-value series confirmed as reported in Section III-B. Abbreviated citations reporting only the endpoints of the coronary fatty streak series omit the intermediate strata.

5) Enos severity breakdown. The overall 77.3 percent figure and mean age are confirmed. The severity breakdown sometimes quoted (35 percent fibrous thickening, 26 percent narrowing of 10 to 49 percent, 15 percent severe) is consistent with secondary sources but was not verified against the 1953 report and is not stated in the body.

6) Adaptive intimal thickening in the Korean War series. The claim that the Enos series classified adaptive intimal thickening as atherosclerosis is an inference from the reported grading criteria, not a statement by the original investigators. It is presented in Section III-C as a methodological caveat.

7) Tsimane calcium prevalence. Correct values are 85 percent with calcium score zero at ages 40 and above, 65 percent at ages 75 and above, and 8 percent with score of 100 or greater in the older stratum. Secondary tables reporting 15 percent and 35 percent Tsimane prevalence in calcified-plaque columns are inversions of the calcium-score-zero data and are erroneous.

8) Familial hypercholesterolemia follow-up. Event rates of 1 versus 26 percent and mortality of 0 versus 7 percent are confirmed. The derived twenty-five-fold reduction framing is not a valid causal effect estimate, for the reasons given in Section IV-C.

9) ApoB-years thresholds. The cumulative-exposure concept is well established, and a cohort-derived inflection near 75 mg/dL per year of usual apoB exposure is reported in CARDIA [19]. The larger round thresholds circulating in secondary literature (5,000 to 6,000 mg/dL-years LDL; 1,300 to 1,500 mg/dL-years apoB) could not be traced to a primary derivation and are identified as heuristics in Section IV-B. An earlier draft of this paper attributed a hazard ratio of 1.05 per 100 mg/dL-years to this literature; that figure could not be located in any primary source and has been replaced with the reported effect estimates.

10) Late-life prevalence figures. PESA and SCAPIS values are confirmed. Not independently verified: carotid plaque of 87 percent at ages 63 to 65 in the ACE 1950 cohort; pooled ARIC and MESA figures of 11 percent with calcium score zero at ages 75 and above and calcium present in 95 percent at ages 90 and above; and 11 percent 非钙化斑块 prevalence among symptomatic patients with calcium score zero. Overstated and not used: obstructive stenosis prevalences of 45 percent at ages 60 to 80 and 65 percent above age 80, microscopic disease approaching 100 percent, and symptomatic disease of 15 to 25 percent.

11) Stary lesion frequencies in infancy and puberty. Commonly cited values (isolated macrophage foam cells in 45 percent of infants within the first eight months; 65 percent with fatty-streak lesions and 8 percent at preatheroma or 动脉粥样硬化斑块 stage in the 12 to 14 year stratum) are consistent with the published series but were not verified against original tables and are not stated numerically.

12) O’Keefe comparative lipid values. Reference [22] is a narrative review and opinion article, not original research. Its reported lipid values for hunter-gatherer populations and wild primates are asserted with limited primary citation and were not independently verified. It is cited in Section V-B as a synthesis of a position rather than as primary evidence.

13) Adaptive intimal thickening prevalence in newborns. The repeated figure of up to 30 percent of newborns could not be traced to a primary source and is not asserted.

14) Pediatric fat restriction threshold. Earlier drafts left unresolved whether fat restriction is contraindicated below 12 months or below two years of age. The apparent conflict reflects two provisions of the same guideline: no fat modification during the first year, and reduced-fat milk permitted between 12 and 24 months for selected children only, within a diet still supplying about 30 percent of calories from fat [47]. Both are now stated in Section VI-B.

Acknowledgment and Disclosures

The author is the founder and sole operator of Curing Heart Disease, LLC, which operates a cardiovascular health education platform and derives revenue from that activity. No external funding was received for this work, and no industry sponsor participated in its design, analysis, or drafting. The author reports no other financial relationships relevant to the subject matter.

This paper is a narrative synthesis of published literature. It involved no new human or animal subjects research and required no ethics approval. It is intended for scientific and professional audiences and does not constitute medical advice.

参考文献

1. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-1374. doi:10.1161/01.cir.92.5.1355
2. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262-1275. doi:10.1161/01.atv.20.5.1262
3. Napoli C, D’Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100(11):2680-2690. doi:10.1172/JCI119813
4. Napoli C, Glass CK, Witztum JL, Deutsch R, D’Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999;354(9186):1234-1241. doi:10.1016/S0140-6736(99)02131-5
5. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb. 1993;13(9):1291-1298. doi:10.1161/01.atv.13.9.1291
6. McGill HC Jr, McMahan CA, Herderick EE, et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 2000;20(3):836-845. doi:10.1161/01.atv.20.3.836
7. Gidding SS, Colangelo LA, Nwabuo CC, et al. PDAY risk score predicts cardiovascular events in young adults: the CARDIA study. Eur Heart J. 2022;43(30):2892-2900. doi:10.1093/eurheartj/ehac009
8. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650-1656. doi:10.1056/NEJM199806043382302
9. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea; preliminary report. J Am Med Assoc. 1953;152(12):1090-1093. doi:10.1001/jama.1953.03690120006002
10. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971;216(7):1185-1187. doi:10.1001/jama.1971.03180330061012
11. Webber BJ, Seguin PG, Burnett DG, Clark LL, Otto JL. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA. 2012;308(24):2577-2583. doi:10.1001/jama.2012.70830
12. Kotwal RS, Mazuchowski EL, Howard JT, et al. Autopsy-Determined Atherosclerosis in Elite US Military Special Operations Forces. J Spec Oper Med. 2021;21(2):19-24. doi:10.55460/RLN9-UQ2X
13. Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015;131(24):2104-2113. doi:10.1161/CIRCULATIONAHA.114.014310
14. Bergström G, Persson M, Adiels M, et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. Circulation. 2021;144(12):916-929. doi:10.1161/CIRCULATIONAHA.121.055340
15. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103(22):2705-2710. doi:10.1161/01.cir.103.22.2705
16. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
17. Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21(10):701-716. doi:10.1038/s41569-024-01039-5
18. Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. JAMA Cardiol. 2021;6(12):1406-1413. doi:10.1001/jamacardio.2021.3508
19. Zheutlin AR, Handoo F, Luebbe S, et al. Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Eur Heart J. 2025;46(41):4302-4312. doi:10.1093/eurheartj/ehaf472
20. Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-1556. doi:10.1056/NEJMoa1816454
21. Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet. 2017;389(10080):1730-1739. doi:10.1016/S0140-6736(17)30752-3
22. O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142-2146. doi:10.1016/j.jacc.2004.03.046
23. Thompson RC, Allam AH, Lombardi GP, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet. 2013;381(9873):1211-1222. doi:10.1016/S0140-6736(13)60598-X
24. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290(4):502-510. doi:10.1001/jama.290.4.502
25. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389
26. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107(2):256-264. doi:10.1542/peds.107.2.256
27. Niinikoski H, Lagström H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;116(9):1032-1040. doi:10.1161/CIRCULATIONAHA.107.699447
28. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336(8708):129-133. doi:10.1016/0140-6736(90)91656-u
29. Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD? J Fam Pract. 2014;63(7):356-364b.
30. Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020;8(8):CD011737. Published 2020 Aug 21. doi:10.1002/14651858.CD011737.pub3
31. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017;136(3):e1-e23. doi:10.1161/CIR.0000000000000510
32. Marklund M, Wu JHY, Imamura F, et al. Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality. Circulation. 2019;139(21):2422-2436. doi:10.1161/CIRCULATIONAHA.118.038908
33. Johnson GH, Fritsche K. Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials. J Acad Nutr Diet. 2012;112(7):1029-1041.e10415. doi:10.1016/j.jand.2012.03.029
34. Su H, Liu R, Chang M, Huang J, Wang X. Dietary linoleic acid intake and blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Food Funct. 2017;8(9):3091-3103. doi:10.1039/c7fo00433h
35. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 1997;79(3):350-354. doi:10.1016/s0002-9149(96)00760-6
36. Vogel RA, Corretti MC, Plotnick GD. The postprandial effect of components of the Mediterranean diet on endothelial function. J Am Coll Cardiol. 2000;36(5):1455-1460. doi:10.1016/s0735-1097(00)00896-2
37. Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013;346:e8707. Published 2013 Feb 4. doi:10.1136/bmj.e8707
38. Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ. 2016;353:i1246. Published 2016 Apr 12. doi:10.1136/bmj.i1246
39. McMahan CA, Gidding SS, Viikari JS, et al. Association of Pathobiologic Determinants of Atherosclerosis in Youth risk score and 15-year change in risk score with carotid artery intima-media thickness in young adults (from the Cardiovascular Risk in Young Finns Study). Am J Cardiol. 2007;100(7):1124-1129. doi:10.1016/j.amjcard.2007.05.035
40. Rask-Nissilä L, Jokinen E, Terho P, et al. Effects of diet on the neurologic development of children at 5 years of age: the STRIP project. J Pediatr. 2002;140(3):328-333. doi:10.1067/mpd.2002.122393
41. Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. doi:10.1093/eurheartj/ehz962
42. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-2639. doi:10.1016/j.jacc.2012.09.017
43. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
44. Peterson MM, Mack JL, Hall PR, et al. Apolipoprotein B is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe. 2008;4(6):555-566. doi:10.1016/j.chom.2008.10.001
45. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957;11(4):398-411. doi:10.1111/j.1558-5646.1957.tb02911.x
46. Wang F, Zheng J, Yang B, Jiang J, Fu Y, Li D. Effects of vegetarian diets on blood lipids: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2015;4(10):e002408. doi:10.1161/JAHA.115.002408
47. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213-S256. doi:10.1542/peds.2009-2107C